Title |
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
|
---|---|
Published in |
Arquivos de Neuro-Psiquiatria, August 2016
|
DOI | 10.1590/0004-282x20160090 |
Pubmed ID | |
Authors |
Yara Dadalti Fragoso, Soniza Vieira Alves-Leon, Jefferson Becker, Joseph Bruno Bidin Brooks, Eber Castro Correa, Alfredo Damasceno, Paulo Diniz da Gama, Rodrigo Assad da Gama, Andre Palma da Cunha Matta, Ernane Pires Maciel, Thereza Cristina d’Avila Winckler |
Abstract |
To assess safety of the switch between natalizumab and fingolimod without a washout period. Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 3% |
Unknown | 34 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 4 | 11% |
Student > Bachelor | 3 | 9% |
Student > Ph. D. Student | 3 | 9% |
Researcher | 3 | 9% |
Student > Doctoral Student | 2 | 6% |
Other | 8 | 23% |
Unknown | 12 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 31% |
Neuroscience | 5 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
Social Sciences | 2 | 6% |
Economics, Econometrics and Finance | 1 | 3% |
Other | 3 | 9% |
Unknown | 10 | 29% |